Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02730468 · ClinicalTrials.gov registry record
SEP-SEQ Trial - Determining the Etiology of Sepsis Using an Infectious Disease Diagnostic Sequencing Assay
A clinical trial of Sepsis, sponsored by Karius.
- Completed
- Registry status
- 350
- Enrollment target
- 1
- Study location
NCT02730468: Completed study of Sepsis, sponsored by Karius.
NCT02730468 is a study of Sepsis that has completed, run by Karius. The registered enrollment target is 350 participants, below the 6,561-participant average among 90 other Sepsis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02730468, a study of Sepsis, has completed, sponsored by Karius.
- COMPLETED
- Registry status
- 350 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the performance of the Karius Infectious Diseases Plasma Sequencing Assay in patients who present to the emergency room with sepsis.
Conditions Studied
Study Locations (1)
California
- Stanford University Hospital - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2016-04 |
| Est. Completion | 2017-10 |
What the finished NCT02730468 record still lists
NCT02730468 is an observational study that tracks outcomes without assigning an intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 6,561-participant average among 90 other Sepsis trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Sepsis appearing as the primary indexed condition, and to 0 interventions.
NCT02730468 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02730468 about?
NCT02730468 is a clinical study titled "SEP-SEQ Trial - Determining the Etiology of Sepsis Using an Infectious Disease Diagnostic Sequencing Assay". The purpose of this study is to evaluate the performance of the Karius Infectious Diseases Plasma Sequencing Assay in patients who present to the emergency room with sepsis.
What is the current status of trial NCT02730468?
This trial is currently completed. The enrollment target is 350 participants. The study started on 2016-04. Estimated completion is 2017-10.
What conditions does trial NCT02730468 study?
This clinical trial studies the following conditions: Sepsis.
Who is sponsoring clinical trial NCT02730468?
This trial is sponsored by Karius, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02730468 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02730468's enrollment target sits among peer trials
350 30th of 90 higher than 60 of 90 other Sepsis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The APS Phenotyping Study
RECRUITING
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
Renin Angiotensin Aldosterone System In Septic Kids
RECRUITING
-
The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls
RECRUITING · NA
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia